ROS cause lipid peroxidation, protein oxidation, and mitochondrial DNA damage, leading to neuronal apoptosis and synaptic dysfunction (Simunkova et al., 2019)
Despite similar weight loss (7-10%), compared with semaglutide monotherapy, the combinations resulted in greater improvements in hepatic steatosis measured by MRI-PDFF (least squares mean of absolute changes: 9.8 to 11.0% versus 8.0%), hepatic biochemistry, and non-invasive tests of fibrosis
Standardized preclinical testing will be necessary in the future to assess the safety of FBA
Research applications often examine cellular communication, peptide binding profiles, metabolic activity, and pathway signaling effects
The effect is smaller than with higher-dose weight-loss formulations